
According to Benzinga Pro data, during Q4, Tarsus Pharmaceuticals (NASDAQ:TARS) posted sales of $338.00 thousand. Earnings were up 5.39%, but Tarsus Pharmaceuticals still reported an overall loss of $14.85 million. Tarsus Pharmaceuticals collected $1.24 million in revenue during Q3, but reported earnings showed a $15.70 million loss.